We Wrote for the Biomere Blog: Here’s What It’s About

By Hannah Sheehan, Ph.D., CEO, CSO & Co-founder, SauveBio

We’re excited to share that SauveBio’s CEO & CSO, Hannah Sheehan, Ph.D., recently contributed a guest post to the Biomere community blog, and it’s about something we talk about with clients constantly.

The piece is called “Protecting Your Preclinical Investment: The Case for High-Fidelity Cell Sorting,” and it makes a single, pointed argument:

Biology doesn’t happen in averages. It happens in specific cells. When you subject precious preclinical samples to bulk analysis, you risk averaging away the exact signal you designed your study to detect.

In vivo studies are expensive, slow, and irreplaceable. The tissue that comes out of them deserves better than a bulk readout. High-fidelity FACS-based cell sorting is the step that turns tissue-level averages into cellular-resolution data, and it’s the difference between a standard safety study and a genuinely informative mechanistic data package.

In the post, we cover three scenarios where sorting isn’t optional:

• Isolating rare immune subsets (TILs, memory B-cells) that represent <1% of a tissue but drive your entire mechanism of action
• Removing dead cells and debris before scRNA-seq to protect your genomics spend and data quality
• Separating GFP+ transduced cells from bystanders in AAV or CRISPR studies to prove on-target efficacy

Each scenario is grounded in the kind of sample types and study designs we see regularly in gene therapy, cell therapy, and complex biologics programs.

Read the full post on the Biomere blog: 

https://biomere.com/community-blog/protecting-your-preclinical-investment-the-case-for-high-fidelity-cell-sorting/

About SauveBio

SauveBio is a Worcester, MA-based flow cytometry and cell sorting CRO. We specialize in FACS-based cell sorting, immunophenotyping, receptor occupancy studies, nanoparticle characterization, antibody validation, and FAMS (fluorescence-activated mitochondrial sorting). We partner with biotech and pharma teams to add cellular resolution to their preclinical and translational workflows.

Want to talk through your study design?  Reach out at info@sauvebio.com

SauveBio to present at PEGS Boston 2026

SauveBio is pleased to announce that we will be presenting at and sponsoring the 22nd Annual PEGS Boston Summit, taking place May 11–15, 2026, at the Omni Boston Hotel at the Seaport in Boston, MA.

As an Innovation Showcase Sponsor, SauveBio’s Co-Founder, CEO & CSO, Hannah Sheehan, Ph.D., will deliver a 15-minute presentation in the Characterization of Novel Biotherapeutics track. Dr. Sheehan will discuss applications of advanced flow cytometry and organelle-level isolation in biotherapeutic research and development — capabilities that operate at a level of resolution not typically accessible through standard CRO workflows.

PEGS Boston is widely regarded as one of the premier annual gatherings for scientists and biopharma leaders working at the forefront of protein and antibody engineering, biotherapeutic development, and biologics characterization. We are proud to be part of the program.

If you or your team will be attending PEGS Boston, we would welcome the opportunity to connect. SauveBio will be available for one-on-one meetings throughout the conference week to discuss how our capabilities in cell sorting and flow cytometric analysis may support your program’s needs.

Event details

• Event: 22nd Annual PEGS Boston Summit
• Dates: May 11–15, 2026
• Location: Omni Boston Hotel at the Seaport, Boston, MA + Virtual
• Track: Characterization of Novel Biotherapeutics
• Sponsorship: Innovation Showcase Sponsor
• Website: PEGSummit.com

Schedule a meeting with our team

We will be scheduling one-on-one meetings throughout the conference week for teams interested in learning more about SauveBio’s services. To reserve time with us, please schedule a meeting or contact us directly.

Setting the Standard: How SauveBio Delivers Trusted Independent Validation for the Biotech Industry

In the fast-moving world of biotechnology, data is the only currency that matters. For reagent developers and manufacturers, internal testing is rarely enough to win over the scientific community. They need unbiased, third-party verification to prove their products work in the hands of others.

That is where SauveBio steps in.

We are proud to announce the successful completion of a high-profile validation project for Identifyn® LLC, a milestone that underscores SauveBio’s growing reputation as a trusted partner for independent scientific analysis.

The SauveBio Difference: Rigor and Reproducibility 

When Identifyn needed to prove the efficacy of their new flow cytometry antibody portfolio, they turned to SauveBio. They didn’t just need a lab; they needed a team with deep expertise in complex assays and a commitment to data integrity.

Our scientific team designed and executed a rigorous head-to-head study, benchmarking new reagents against established industry competitors. The project required high-level proficiency in flow cytometry, specifically targeting complex DNA damage response proteins like BRCA1 and PARP1, targets that are notoriously difficult to stain with precision.

Delivering Actionable Intelligence 

The success of this project highlights a core strength of SauveBio: our ability to deliver clear, definitive answers.

Through our independent analysis, we were able to quantify specificity, signal-to-noise ratios, and cross-reactivity. The data we generated didn’t just validate a product; it provided our client with the independent verification necessary to go to market with confidence.

Your Partner for Scientific Validation 

This announcement is more than just a press release; it is proof of SauveBio’s capability to handle critical validation workflows for the life sciences industry. Whether it is oncology, immunology, or neurobiology, our lab provides the “stamp of approval” that turns a new product into a trusted tool.

We are proud to have facilitated this success and look forward to continuing to provide the rigorous, independent data that drives the biotech industry forward.

[Read the full press release here]

Beyond the Powerhouse: Why Mitochondrial Heterogeneity is the Next Frontier in Research (And How to Measure It)

In the world of precision medicine, the ‘average’ is often the enemy of the truth.

It is perhaps the most persistent sentence in biology education: “The mitochondria are the powerhouse of the cell.” While technically true, this singular definition has arguably held back our understanding of these organelles for decades.

Recent explosions in cell biology research have revealed that mitochondria are far more than static energy generators. They are dynamic signaling hubs, gatekeepers of cell death, regulators of immunity, and critical players in aging and neurodegeneration.

But here is the challenge for modern researchers: Mitochondria are not uniform.

If you are researching complex diseases ranging from cancer to metabolic disorders, treating your mitochondrial population as a single, homogenous population is no longer enough. To push your research forward, you need to look at the individual organelle.

The New Era: Mitochondria as Decision Makers

The narrative has shifted. It is no longer just about bioenergetics; it is about cellular governance. We are witnessing a surge in literature identifying mitochondria as the central processing units of the cell, driving critical decisions in:

• Immune Modulation: Mitochondria are now seen as central to innate immunity, driving signaling cascades that determine how immune cells respond to threats.
• Cell Fate & Apoptosis: They hold the keys to cell survival, releasing cytochrome c to trigger apoptosis when necessary, or failing to do so in cancer cells.
• Calcium Buffering & Signaling: They regulate intracellular calcium levels, influencing everything from muscle contraction to neurotransmitter release.
• Biosynthesis: Distinct subpopulations of mitochondria may prioritize building cellular “blocks” (lipids, proteins) over generating energy, depending on the cell’s immediate needs.

The Bulk Analysis Blind Spot

Despite this complexity, many labs still rely on bulk analysis methods like Western blotting or whole-cell respirometry.

While these methods provide a useful average, they mask the critical details. In a single cell, you might have a subpopulation of healthy, hyper-polarized mitochondria alongside a subpopulation of damaged, depolarized ones. A bulk assay averages these two groups, potentially showing a “normal” result when the reality is a state of cellular crisis.

In diseases like Parkinson’s or Alzheimer’s, where only a fraction of mitochondria may be dysfunctional initially, this averaging effect can hide the very mechanism you are trying to discover.

Enter FAMS: Analyzing the Organelle, Not the Average

At SauveBio, we specialize in FAMS (Fluorescence-Activated Mitochondria Sorting). This isn’t just standard flow cytometry applied to small things; it is a specialized, nanoscale approach that allows us to analyze and sort individual mitochondria.

By treating mitochondria as distinct entities, FAMS allows you to:

1. Uncover Heterogeneity: distinct subpopulations based on membrane potential, size, or protein expression.

2. Sort for Downstream Analysis: Isolate the specific “bad actors” (dysfunctional mitochondria) from the healthy pool for sequencing or proteomic analysis.

3. High-Throughput Sensitivity: Analyze thousands of organelles per second with a level of resolution that microscopy cannot match and bulk assays cannot provide.

The SauveBio Advantage

At SauveBio, we don’t just run samples; we partner with you to design the flow cytometry panels that will answer your specific biological questions. Whether you are investigating the metabolic shift in T-cells or the mitochondrial toxicity of a new drug candidate, FAMS offers the granularity required to publish high-impact data in this evolving field.

Ready to look beyond the powerhouse?

If your research relies on mitochondrial function, stop settling for the average. Contact SauveBio today to discuss how FAMS can reveal the hidden data in your samples.

Better Together: Expanding Endpoint Analysis with Flow Cytometry

How the SauveBio and Biomere partnership is streamlining preclinical workflows.

In the complex world of drug development, the transition between in vivo studies and downstream analysis is often where logistical headaches happen. Samples degrade, timelines drag, and coordination between vendors can become a full-time job.

At SauveBio, we believe that workflow should be seamless.

We are excited to share a recent conversation featuring our very own Hannah Sheehan, who sat down with the team at Biomere to discuss exactly how we are solving these challenges. In this new podcast episode, we dive deep into the “symbiotic” partnership between our two organizations and what it means for the future of endpoint analysis.

The “Symbiotic” Partnership

As discussed in the episode, the collaboration between SauveBio and Biomere is designed to bridge the gap between the vivarium and the flow cytometry lab.

By integrating SauveBio’s advanced cell sorting and flow cytometry capabilities directly with Biomere’s preclinical resources, we offer our clients a unified solution. This means samples don’t just “go to a lab”, they move through a coordinated pipeline designed to maximize cell viability and data quality.

What We Cover in the Episode

If you are involved in preclinical research, immunology, or drug discovery, this conversation is for you. Hannah and Anjli break down:

• The Role of Flow Cytometry: Why high-parameter sorting is becoming the gold standard for endpoint analysis in modern therapeutics.
• Custom Applications: How we tailor our sorting strategies to fit specific study goals, whether it’s rare cell isolation or broad immunophenotyping.
• The Client Experience: What “expanded services” actually looks like for the researchers we support.

Watch the Full Conversation

Ready to see how we are redefining the preclinical workflow? Watch the full podcast episode below to hear Hannah Sheehan and the Biomere team discuss the science, the strategy, and the future of our partnership.

If you’ve ever spent a long day at the flow cytometer only to be rewarded with blank plots or hopelessly high background, you know the frustration. You blame the antibody, the cells, or maybe even the cytometer. But more often than not, the real culprit is a step we often rush through: fixation and permeabilization.

In intracellular flow cytometry, these two steps aren’t just a formality, they are the most critical decision point of your entire protocol. Your choice here is a fundamental trade-off that will determine which proteins you can see, which dyes you can use, and ultimately, whether your data is even valid.

At SauveBio, we believe great data comes from great protocols. Let’s break down this crucial process so you can design your next experiment with confidence.

The Core Mission: What Are We Trying to Do?

Before we dive into the “how,” let’s clarify the “why.” We have two distinct goals:

1. Fixation: This step locks all cellular components in place, preserving a “snapshot” of the cell’s state at that exact moment. It cross-links proteins and prevents them from degrading or leaking.
2. Permeabilization: This step creates holes in the cell membranes. Without it, your large antibodies have no way to get inside the cell to find their targets.

The challenge? The best way to “fix” isn’t always the best way to “perm,” and the chemicals involved can have dramatic, unforeseen consequences for your experiment.

The Fork in the Road: Two Main Strategies

Your protocol will almost always be built on one of two foundational methods for fixation. Your choice here will dictate everything that follows.

Strategy 1: Cross-linking Fixatives (e.g., Paraformaldehyde – PFA)

This is the most common approach, and for good reason. PFA works by creating a “protein net,” chemically linking proteins to each other and to the cellular structure.

• How it Works: PFA is excellent at preserving cell structure and, crucially, trapping soluble proteins (like cytokines) inside the cell before they leak out.
• The Catch: PFA only fixes. It does not permeabilize. You must add a separate permeabilization agent (a detergent) afterward.

Your Detergent Choice is Key:

• For Cytoplasmic Targets (e.g., IFN-γ): Use a mild detergent like Saponin. Saponin selectively pokes temporary holes in the cholesterol-rich plasma membrane, leaving the nuclear membrane intact. It’s gentle on surface markers and most fluorophores.
• For Nuclear Targets (e.g., FoxP3, Ki-67): Use a strong detergent like Triton X-100. Triton is the “wrecking ball”—it dissolves all membranes, including the nucleus, giving your antibodies access to transcription factors and other nuclear proteins.

Strategy 2: Precipitating/Solvent Fixatives (e.g., Methanol)

This is a harsher, “all-in-one” method.

• How it Works: Cold methanol acts as both a fixative and a permeabilizer. It works by rapidly dehydrating the cell and denaturing (precipitating) its proteins, which makes them insoluble and opens up all membranes.
• Best Use: This method is the gold standard for many nuclear signaling (Phosflow) protocols, as it’s highly effective at exposing epitopes for phospho-specific antibodies.

The Consequences: How Your Choice Impacts Everything

This is where the trade-offs become critical. The method you choose will directly affect every other part of your experiment.

1. Impact on Your Target Antigen (Epitope)

The “epitope” is the specific part of the protein your antibody binds to.

• PFA can mask epitopes. The “protein net” it creates can physically block your antibody’s binding site or change its shape.
• Methanol can destroy some epitopes by denaturing them. However, for other targets, this denaturation is beneficial, uncoiling the protein and exposing an epitope that PFA would have hidden.

2. Impact on Your Fluorescent Dyes (Fluorophores)

This is the most common and costly pitfall.

• Methanol is the main culprit. It irreversibly destroys protein-based fluorophores. This includes Phycoerythrin (PE), Allophycocyanin (APC), and all their tandem dyes (e.g., PE-Cy7, APC-R700).
• If your protocol requires methanol, you CANNOT use these dyes. You must build your panel with methanol-resistant small-molecule dyes (like FITC, Alexa Fluors, or Brilliant Violets).
• PFA is generally safe for all dyes, but it can increase the cell’s natural autofluorescence, which can make it harder to see dim signals.

3. Impact on Your Surface Markers

Pro Tip: Always stain your surface markers FIRST on live, happy cells.

This is our “Rule of Thumb” for a reason. Harsh reagents like Methanol and Triton X-100 can damage or strip surface markers, causing you to lose that precious signal. By staining your live cells with your surface antibodies before you fix and permeabilize, you lock in that signal, regardless of how harsh your intracellular protocol is.

Quick Protocol Cheat Sheet

Here’s how to match your goal to the right protocol.

• Goal: Staining cytoplasmic cytokines (e.g., IFN-γ, IL-4)
  • Protocol: PFA fixation, followed by Saponin permeabilization.
  • Why: PFA traps the cytokines, and Saponin is gentle enough to open the plasma membrane without destroying surface markers or PE/APC dyes.
• Goal: Staining nuclear transcription factors (e.g., FoxP3)
  • Protocol: PFA fixation, followed by Triton X-100 permeabilization.
  • Why: PFA fixes the cell, and Triton is strong enough to punch holes in the nuclear membrane. (Just remember to stain surface markers first!)
• Goal: Staining phospho-proteins (“Phosflow,” e.g., pSTAT5)
  • Protocol: PFA fixation (immediate!), followed by Methanol permeabilization.
  • Why: This is a special two-step. PFA is used first to “freeze” the transient phosphorylation state. Then, methanol is used to permeabilize, as it’s superior for this class of target.
  • Critical Trade-off: You cannot use PE or APC dyes with this protocol.

A Final Word

There is no single “best” protocol. The “right” method is the one that is optimized for your specific antigen, your cell type, and your experimental questions. Taking the time to understand these trade-offs is the first and most important step toward clean, reliable, and publication-quality data.

At SauveBio, we’re obsessed with protocol optimization. Designing and executing complex flow cytometry experiments is what we do every day. If you want to get the most out of your samples without the headache of troubleshooting, let our experts handle it for you.

Contact us to discuss your project, and let us turn your complex biological questions into high-quality, actionable data you can trust.

Splice Histology and SauveBio are thrilled to announce a collaborative partnership designed to streamline pre-clinical research for the biotech and pharmaceutical communities.

Splice Histology provides customers with expert driven histology, IHC, and IF assay development with their board-certified histologists at the helm of tissue workflow. With their science-first approach, they partner with their clients to ensure that your histological and assay development needs are met with the highest standards of rigor, reproducibility, and translational relevance.

Together, Splice and SauveBio create a seamless workflow, from tissue processing, to assay development, to single-cell and spatial analysis. By bridging morphological context with phenotypic depth, researchers can:

• Correlate tissue structure with cellular function by combining IHC/IF results with single cell-resolution flow cytometry data to gain deeper mechanistic insights
• Isolate novel cell populations first identified using histology for downstream studies
• Accelerate translational research with more robust pre-clinical data for drug discovery and biomarker development

With both organizations located in Worcester, communication and sample logistics are streamlined. This enables quicker turnaround times, greater consistency, and efficient scientific collaboration.

We invite you to contact Splice Histology or SauveBio to explore how this partnership can accelerate your pre-clinical workflows. Together, we can advance research with expertise and reliability, on a foundation of scientific collaboration, helping each other advance discovery with transparent communication.

October is Breast Cancer Awareness Month, a time marked by pink ribbons that symbolize solidarity and hope for millions affected by this disease. This awareness is crucial, but behind the symbol lies an ongoing, intricate battle fought by researchers in labs worldwide. At SauveBio, we are proud to contribute to this fight by providing powerful tools that help scientists look deeper into the biology of cancer.

What is Flow Cytometry? A High-Speed Cellular Inspection

Imagine you need to inspect thousands of individual cells, not just to see what they look like, but to understand what’s happening inside and on their surface. Doing this one by one under a microscope would be impossible.

Flow cytometry solves this problem with incredible speed and precision. Think of it like a high-tech, microscopic sorting machine.

• Single File Line: A fluidic system lines up cells from a sample to pass one-by-one through a laser beam.
• The Laser Interrogation: As each cell zips through the laser, it scatters light in a unique way, which tells us about its size and internal complexity.
• Fluorescent Tags: The real power comes from fluorescent markers, or antibodies, that we can attach to specific proteins (biomarkers) on or inside the cells. When the laser hits these tags, they glow with specific colors.
• Data Collection: Sensitive detectors capture the scattered and fluorescent light from every single cell, translating it into a massive, multi-parameter dataset.

In minutes, we can analyze tens of thousands of cells, creating a detailed cellular snapshot of the sample.

How Flow Cytometry Accelerates Breast Cancer Research

This technology isn’t just about counting cells; it’s about understanding the complex ecosystem of a tumor. For breast cancer, flow cytometry allows researchers to:

• Characterize Tumor Heterogeneity: Tumors are not uniform masses. They are a complex mix of different cancer cells and supporting cells. Flow cytometry can dissect this complexity, identifying subpopulations of cells with different characteristics, which can be crucial for understanding why some cancers resist treatment.
• Identify Cancer Stem Cells (CSCs): A small population of cells within a tumor, known as CSCs, are often responsible for metastasis and recurrence. Flow cytometry can identify these rare but dangerous cells by detecting their unique surface markers, allowing researchers to study how to target them specifically.
• Monitor Treatment Efficacy: Is a new drug working? We can treat cancer cells with a compound and then use flow cytometry to see if it’s pushing them into apoptosis (programmed cell death) or halting their cell cycle. This provides rapid feedback on a drug’s potential.
• Analyze the Immune Response: The field of immuno-oncology is revolutionizing cancer treatment. Flow cytometry is essential for profiling the immune cells (like T-cells) that infiltrate a tumor, helping researchers understand how the body’s own immune system is fighting the cancer and how new therapies can boost that fight.

SauveBio’s Capabilities: Partnering in Discovery

At SauveBio, we provide comprehensive flow cytometry services to empower our partners in their research. A cornerstone of our breast cancer research capabilities involves working with established and well-characterized cell lines, such as the MCF7 cell line.

The MCF7 line is an estrogen-receptor (ER) positive cell line, which is critical because it represents a model for the most common type of breast cancer (~70% of cases). Using our advanced flow cytometry panels, we can help researchers answer pivotal questions. For example, we can:

• Analyze how a novel estrogen-receptor antagonist affects the cell cycle of MCF7 cells.
• Measure the expression of key survival proteins within MCF7 cells after treatment with a new therapeutic agent.
• Quantify apoptosis to determine the precise dose-response of a potential new drug.

By providing high-quality, reproducible data, we help accelerate the journey from a promising idea in the lab to a potential therapy for patients.

This October, as we honor the patients, survivors, and families affected by breast cancer, we also recognize the dedicated researchers pushing the boundaries of science. SauveBio is committed to being their partner, providing the tools and expertise needed to turn research into hope.

Ready to advance your cancer research? Contact the experts at SauveBio to learn how our flow cytometry services can illuminate your path to discovery.

Immuno-oncology (IO) is one of the most promising fields in cancer treatment, and flow cytometry is playing a key role in advancing it. Flow cytometry allows researchers to analyze immune cells and their interactions with cancer cells, providing deeper insights into how the immune system can be harnessed to fight cancer.

Profiling Immune Cells:

Flow cytometry is used extensively to profile immune cells involved in cancer progression. By tagging cells with specific antibodies, scientists can sort and analyze different types of immune cells such as T-cells, NK cells, and dendritic cells. This helps researchers understand how these cells interact with tumor cells and how they respond to cancer treatments.

For example, in immunotherapy, the effectiveness of treatments such as immune checkpoint inhibitors can be measured using flow cytometry. Researchers can assess the expression of immune checkpoint proteins such as PD-1 or CTLA-4 on immune cells, providing valuable information on why some patients respond well to treatment and others do not.

Monitoring Tumor Microenvironment:

Another important aspect of immuno-oncology research is understanding the tumor microenvironment (TME). Flow cytometry helps researchers study the TME by identifying immune cells infiltrating the tumor and monitoring their activation status. By characterizing immune cell populations in and around the tumor, scientists can determine how well immune cells are being recruited and activated to attack the cancer.

This also helps to identify factors within the TME that may be preventing effective immune responses, such as immune suppressive cells (like Tregs) or checkpoint inhibitors. Understanding these dynamics is key to improving immunotherapies, as it opens the door to strategies that can enhance immune cell function within the tumor.

Tracking Treatment Responses:

In clinical trials, flow cytometry is crucial for tracking how patients are responding to immunotherapies. By regularly profiling immune cell populations and monitoring specific markers, researchers can get real-time data on how patients are reacting to treatment. This allows for a more personalized approach to therapy, with the ability to adjust treatment plans based on immune cell activity.

For instance, the expansion of specific T-cell populations can indicate a robust immune response to a cancer vaccine or checkpoint inhibitor. On the flip side, the presence of immune suppressive cells in the TME might signal that the treatment isn’t working as well as expected.

Flow Cytometry in CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapies are revolutionizing cancer treatment, and flow cytometry is essential in monitoring the process. Flow cytometry is used to track the quantity and quality of CAR-T cells in patients, as well as their activation and persistence. This is critical for understanding how CAR-T cells are interacting with cancer cells, and whether they are maintaining efficacy over time.

Through flow cytometry, researchers can also monitor the potential toxicities of CAR-T therapies, including cytokine release syndrome (CRS), ensuring that patients are not only benefiting from treatment but are also being closely monitored for side effects.

Conclusion

As immuno-oncology continues to evolve, flow cytometry will remain an indispensable tool for unlocking new insights into cancer and how the immune system can be leveraged to fight it. Whether it’s profiling immune cells, tracking tumor progression, or monitoring the success of treatments like CAR-T or immune checkpoint inhibitors, flow cytometry is at the forefront of IO research, helping bring us closer to more effective, personalized cancer therapies.